EP0918525A1 - Verwendung von mifepriston zur behandlung von psychosen und suchtverhalten - Google Patents

Verwendung von mifepriston zur behandlung von psychosen und suchtverhalten

Info

Publication number
EP0918525A1
EP0918525A1 EP97952079A EP97952079A EP0918525A1 EP 0918525 A1 EP0918525 A1 EP 0918525A1 EP 97952079 A EP97952079 A EP 97952079A EP 97952079 A EP97952079 A EP 97952079A EP 0918525 A1 EP0918525 A1 EP 0918525A1
Authority
EP
European Patent Office
Prior art keywords
mifepristone
psychoses
treatment
receptors
dopamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97952079A
Other languages
English (en)
French (fr)
Inventor
Claude Oberlander
Pier Vincenzo-Université de Bordeaux II PIAZZA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of EP0918525A1 publication Critical patent/EP0918525A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol

Definitions

  • the present invention relates to the application of mifepristone having an antiglucocorticoid activity for the preparation of medicaments intended for the prevention or
  • Products with anti-glucocorticoid activity are known as being able to be used as medicaments to fight mainly against the side effects of glucocorticoids; they also help fight
  • glucocorticoids It is very likely that glucocorticoid hormones modify the activity of these neurons by an action on these receptors.
  • 35 anti-dopaminergics In fact, they very significantly decrease the basal release of dopamine and the release of dopamine caused by depolarizing stimuli. The release of dopamine is considered to be one of the para- most reliable meters to assess dopamine activity.
  • the present invention therefore relates to the application of mifepristone corresponding to the formula:
  • the subject of the present invention is therefore the application of mifepristone having an antiglucocorticoid activity with the exception of mifepristone for the preparation of medicaments intended for the prevention or treatment on the one hand of schizophrenia and manic states , and on the other hand compulsive consumption behavior towards drugs such as opiates, psychostimulants, bartiturics and cannabis (or derivatives), nicotine or alcohol, disorders of eating behavior such as bulimia and compulsive behaviors like pathological gambling.
  • the invention extends to pharmaceutical compositions containing as active ingredient mifepristone.
  • the useful dosage varies depending on the type of psychosis or addiction to be prevented or treated and the route of administration. It can vary from 1 to 1000 mg per day in adults orally.
  • VTA ventral tegmental area
  • This behavioral response specifically depends on the activation of the dopaminergic neurons of the midbrain. Blockage of type II receptors also decreases the locomotor response to intra-ATV injection of morphine.
  • type II receptors we examined how type II receptors can exert their effects on the dopaminergic system. For this, we measured by intracerebral microdialysis the effect of blocking these receptors on the release of dopamine in the nucleus accumbens. A very significant decrease (more than 50%) of extracellular dopamine concentrations has been observed. the basal state and in response to morphine. It is important to note that the administration of type II receptor antagonists does not affect motor behavior. These substances have no effect either on the locomotor response to a new environment, or on the locomotor response to an injection of solvent (0.9% NaCl).
  • Dopamine release is estimated by direct measurement of its extracellular concentrations.
  • Spironolactone (1 ⁇ m) or 173-hydroxy 10 / 3- [(4-methylphenyl) methyl] 17 ⁇ - (prop-1-ynyl) estra 4, 9 (11) -dien-3 -one (200 nM) have have been used to block type I corticosteroid receptors or type II corticosteroid receptors, respectively.
  • the dopaminergic neurons are characterized by a basal release of TTX-sensitive dopamine and dependent Ca and by a release caused by K + , also, Ca 2+ dependent. In addition, these neurons express presynaptic receptors and functional reuptake sites.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
EP97952079A 1996-12-19 1997-12-17 Verwendung von mifepriston zur behandlung von psychosen und suchtverhalten Withdrawn EP0918525A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9615649A FR2757400B1 (fr) 1996-12-19 1996-12-19 Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs
FR9615649 1996-12-19
PCT/FR1997/002321 WO1998026785A1 (fr) 1996-12-19 1997-12-17 Utilisation de mifepristone pour le traitement des psychoses et des comportements addictifs

Publications (1)

Publication Number Publication Date
EP0918525A1 true EP0918525A1 (de) 1999-06-02

Family

ID=9498861

Family Applications (2)

Application Number Title Priority Date Filing Date
EP97952078A Withdrawn EP0892641A1 (de) 1996-12-19 1997-12-17 Verwendung von antiglucocorticoid-verbindungen zur behandlung von psychosen oder suchtverhalten
EP97952079A Withdrawn EP0918525A1 (de) 1996-12-19 1997-12-17 Verwendung von mifepriston zur behandlung von psychosen und suchtverhalten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP97952078A Withdrawn EP0892641A1 (de) 1996-12-19 1997-12-17 Verwendung von antiglucocorticoid-verbindungen zur behandlung von psychosen oder suchtverhalten

Country Status (4)

Country Link
EP (2) EP0892641A1 (de)
AU (2) AU5563398A (de)
FR (1) FR2757400B1 (de)
WO (2) WO1998026785A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69835225T2 (de) * 1997-10-06 2007-07-05 The Board Of Trustees Of The Leland Stanford Junior University, Palo Alto Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen
EP1726307A3 (de) * 1997-10-06 2007-04-04 The Board Of Trustees Of The Leland Stanford Junior University Methode zur Behandlung von durch Glycocorticoidstörungen verursachten Psychosen
MXPA01011018A (es) 1999-04-30 2002-05-06 Pfizer Prod Inc Moduladores del receptor glucocorticoide.
US7713989B2 (en) 2000-04-27 2010-05-11 Dow Robert L Glucocorticoid receptor modulators
DE60113032T2 (de) 2000-10-30 2006-07-06 Pfizer Products Inc., Groton Glukokortikoidrezeptor-Modulatoren
CN1853722A (zh) * 2001-07-23 2006-11-01 科塞普特治疗公司 预防由抗精神病药物引起的体重增加的方法
US7326697B2 (en) * 2002-04-29 2008-02-05 Corcept Therapeutics, Inc. Methods for increasing the therapeutic response to electroconvulsive therapy
EP1862468A1 (de) 2006-06-02 2007-12-05 Bayer Schering Pharma Aktiengesellschaft Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
WO2011150209A1 (en) 2010-05-26 2011-12-01 Corcept Therapeutics, Inc. Treatment of muscular dystrophy
CN118251415A (zh) * 2021-10-29 2024-06-25 清华大学 用于治疗或诊断精神分裂症的方法和产品
CN114652730A (zh) * 2021-12-08 2022-06-24 中国科学院深圳先进技术研究院 米非司酮干预和治疗尼古丁成瘾的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995004536A1 (en) * 1993-08-04 1995-02-16 Akzo Nobel N.V. Antiglucocorticoid steroids for the treatment of anxiety disorders
FR2718354B1 (fr) * 1994-04-08 1996-05-03 Roussel Uclaf Application des composés antiglucocorticoïde pour la préparation de médicaments destinés à la prévention ou au traitement des manifestations liées au syndrome de sevrage des narcotiques et les compositions les renfermant.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9826785A1 *

Also Published As

Publication number Publication date
AU5563398A (en) 1998-07-15
AU5563298A (en) 1998-07-15
EP0892641A1 (de) 1999-01-27
FR2757400B1 (fr) 1999-12-17
WO1998026783A1 (fr) 1998-06-25
FR2757400A1 (fr) 1998-06-26
WO1998026785A1 (fr) 1998-06-25

Similar Documents

Publication Publication Date Title
EP0918525A1 (de) Verwendung von mifepriston zur behandlung von psychosen und suchtverhalten
Follesa et al. Role of allopregnanolone in regulation of GABAA receptor plasticity during long-term exposure to and withdrawal from progesterone
Wolf et al. Actions of dehydroepiandrosterone and its sulfate in the central nervous system: effects on cognition and emotion in animals and humans
Lupien et al. Increased cortisol levels and impaired cognition in human aging: implication for depression and dementia in later life
Behan et al. Sex steroid hormones and the neural control of breathing
Reddy Neurosteroids and their role in sex-specific epilepsies
EP1858501A1 (de) Nmda-rezeptor-antagonisten bei der medizinischen intervention von stoffwechselerkrankungen
KR100895662B1 (ko) 글루코코르티코이드 수용체 특이적 길항제를 이용한스트레스 장애의 치료 방법
Ramôa et al. Diminished role of dopamine D1-receptor signaling with the development of an addicted phenotype in rats
Summers et al. Serotonergic responses to corticosterone and testosterone in the limbic system
Gorzalka et al. Sexual behavior and wet dog shakes in the male rat: regulation by corticosterone
Eaton et al. Self-injurious behavior is decreased by cyproterone acetate in adult male rhesus (Macaca mulatta)
Shiono et al. Limbic progesterone receptor activity enhances neuronal excitability and seizures
US7884091B2 (en) Methods for treating delirium using glucocorticoid receptor-specific antagonists
Mondelli et al. Neuroendocrine effects of citalopram infusion in anorexia nervosa
JP2021519799A (ja) 物質離脱障害を治療するためのｇａｂａ−ａアンタゴニスト
EP1390037B1 (de) Verwendung von glucocorticoid-rezeptor-spezifischen antagonisten zur behandlung von delirium
Gillen et al. Synergistic anorectic effect of dehydroepiandrosterone and d-fenfluramine on the obese Zucker rat
EP0938311B1 (de) Verwendung von efaroxan zur herstellung eines arzneimittels zur behandlung von huntington krankheit
AU2002303652A1 (en) Methods for treating delirium using glucocorticoid receptor-specific antagonists
AU2006233254B8 (en) Methods for treating delirium using glucocorticoid receptor-specific antagonists
JP2001513800A (ja) 医薬組成物調製のためのピバガビンの使用
Franklin et al. Increases in preproenkephalin mRNA levels in the Syrian hamster: The influence of glucocorticoids is dependent on age and tissue
ZA200308910B (en) Method for treating delerium using glucocorticoid receptor-specific antagonists
WO1998008493A1 (fr) Utilisation d'antagonistes 5-ht4 dans la regulation de la secretion de corticosteroides

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980921

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20010515

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20011127